NCT06716203View on ClinicalTrials.gov

A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

PHASE3RecruitingINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

December 29, 2025

Study Completion Date

August 25, 2026

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

Drug: 5 mg BGM0504 Administered SC

Drug: BGM0504 Administered SC

DRUG

Drug: : 10 mg BGM0504 Administered SC

Drug: BGM0504 Administered SC

DRUG

Drug: Placebo Administered SC

Drug: Placebo Administered SC

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
collaborator

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.

INDUSTRY

lead

BrightGene Bio-Medical Technology Co., Ltd.

INDUSTRY